Ueberroth BE - Search Results

1

Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma.

Ueberroth BE, Jones JC, Bekaii-Saab TS. Ueberroth BE, et al. Pancreatology. 2022 Sep;22(6):741-748. doi: 10.1016/j.pan.2022.06.009. Epub 2022 Jun 12. Pancreatology. 2022. PMID: 35725696 Review.

2

Neuroendocrine Carcinoma of the Anus and Rectum: Patient Characteristics and Treatment Options.

Ueberroth BE, Liu AJ, Starr JS, Hobday TJ, Ashman JB, Mishra N, Bekaii-Saab TS, Halfdanarson TR, Sonbol MB. Ueberroth BE, et al. Clin Colorectal Cancer. 2021 Jun;20(2):e139-e149. doi: 10.1016/j.clcc.2020.12.001. Epub 2020 Dec 17. Clin Colorectal Cancer. 2021. PMID: 33551318

3

Osteoclast-Like Giant Cell Tumors of the Pancreas: Clinical Characteristics, Genetic Testing, and Treatment Modalities.

Ueberroth BE, Liu AJ, Graham RP, Bekaii-Saab TS, McWilliams RR, Mahipal A, Truty MJ, Mody K, Sonbol MB, Halfdanarson TR. Ueberroth BE, et al. Pancreas. 2021 Aug 1;50(7):952-956. doi: 10.1097/MPA.0000000000001858. Pancreas. 2021. PMID: 34369897

4

The role of circulating tumor DNA in evaluating minimal residual disease in luminal gastrointestinal malignancies.

Ueberroth BE, Jones JC, Bekaii-Saab T. Ueberroth BE, et al. Clin Adv Hematol Oncol. 2022 Jul;20(7):444-455. Clin Adv Hematol Oncol. 2022. PMID: 35802877 Review.

5

Changes in Prescribing Patterns in Stage III Colon Cancer.

Ou FS, Walden DJ, Larson JJ, Kang S, Griswold CR, Ueberroth BE, Patel B, Draper A, Raman P, Alese OB, Sonbol MB, Bekaii-Saab TS, Wu CS, Ahn DH. Ou FS, et al. Among authors: ueberroth be. J Natl Compr Canc Netw. 2023 Aug;21(8):841-850.e4. doi: 10.6004/jnccn.2023.7028. J Natl Compr Canc Netw. 2023. PMID: 37549913

6

Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma.

Ueberroth BE, Khan A, Zhang KJ, Philip PA. Ueberroth BE, et al. J Gastrointest Cancer. 2021 Mar;52(1):160-168. doi: 10.1007/s12029-020-00378-z. J Gastrointest Cancer. 2021. PMID: 32077005

7

The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.

Liu AJ, Kosiorek HE, Ueberroth BE, Jaeger E, Ledet E, Kendi AT, Tzou K, Quevedo F, Choo R, Moore CN, Ho TH, Singh P, Keole SR, Wong WW, Sartor O, Bryce AH. Liu AJ, et al. Among authors: ueberroth be. Prostate. 2022 Sep;82(12):1202-1209. doi: 10.1002/pros.24375. Epub 2022 Jun 2. Prostate. 2022. PMID: 35652618

8

Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.

Liu AJ, Ueberroth BE, McGarrah PW, Buckner Petty SA, Kendi AT, Starr J, Hobday TJ, Halfdanarson TR, Sonbol MB. Liu AJ, et al. Among authors: ueberroth be. Oncologist. 2021 May;26(5):383-388. doi: 10.1002/onco.13686. Epub 2021 Feb 8. Oncologist. 2021. PMID: 33496040 Free PMC article.

9

The use of 3'-deoxy-3'-¹⁸F-fluorothymidine (FLT) PET in the assessment of long-term survival in breast cancer patients treated with neoadjuvant chemotherapy.

Ueberroth BE, Lawhorn-Crews JM, Heilbrun LK, Smith DW, Akoury J, Ali-Fehmi R, Eiseler NT, Shields AF. Ueberroth BE, et al. Ann Nucl Med. 2019 Jun;33(6):383-393. doi: 10.1007/s12149-019-01345-w. Epub 2019 Feb 27. Ann Nucl Med. 2019. PMID: 30810980 Free PMC article. Clinical Trial.

10

Multicancer Early detection Panels (MCEDs) in the Primary Care Setting.

Ueberroth BE, Marks LA, Borad MJ, Agrwal N. Ueberroth BE, et al. Am J Med. 2022 Jul;135(7):e145-e149. doi: 10.1016/j.amjmed.2022.03.006. Epub 2022 Apr 1. Am J Med. 2022. PMID: 35367445 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page